Your browser does not support JavaScript!

Matières premières

351 entreprises et organismes intervenants dans le domaine 'Matières premières', classés par activité.

Rejoignez la communauté
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

Cidara posts data from head-to-head trial against Merck antifungal

Il y a 3 semaines
A phase 2 trial of Cidara Therapeutics’ antifungal prospect rezafungin has met its objectives. The trial found the drug performed numerically better than Merck’s Cancidas, offering Cidara...
www.fiercebiotech.com
Nouvelle réponse - Il y a 3 semaines
Quelle est la composition de la primocin ?
INVIVOGEN
à répondu :

Bonjour;
Merci de votre intérêt pour ce produit. Malheureusement la formulation de ce produit est confidentielle. Cet antibiotique est extrêmement efficace contre toute contamination microbienne et tout particulièrement pour les cellules primaires du fait de sa faible toxicité.

MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 3 semaines

Intec flunks phase 3 Parkinson's test against Merck drug

Le 22/07/2019
A phase 3 trial of Intec Pharma’s Parkinson's disease drug has missed its primary endpoint, sparking a steep decline in the company’s stock. The candidate uses a drug delivery system designed to...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Il y a 3 semaines

Turning Shelved Drugs into a New Promise for Immuno-Oncology

Le 22/07/2019
After working for 12 years at Merck, Catherine Pickering decided to take a risk and create iOnctura, a spin-out company exploring a new application in immuno-oncology for a drug candidate that had...
labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 08/07/2019

Subtle chemical shift reverses prediabetes in Merck-partnered mouse trial

Le 02/07/2019
Targeting fatty lipids known as ceramides could reverse insulin resistance and fatty liver, scientists from the University of Utah and Merck Research Laboratories discovered. They've shown in...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Le 20/06/2019

EU Gives Lynparza Green Light as First-Line Ovarian Cancer Treatment

Le 19/06/2019
The DNA damage repair drug olaparib (Lynparza), developed by AstraZeneca and Merck, has been approved by the EU as a first-line treatment preventing the return of ovarian cancer after initial...
labiotech.eu
ABBOTT
est cité dans une actualité de FierceBiotech
Le 18/06/2019

Abbott launches 3-minute, in-office A1c blood test for diagnosing diabetes

Le 17/06/2019
Abbott has launched its new point-of-care diabetes blood test that can provide hemoglobin A1c results in only three minutes, allowing clinicians to develop and start care plans within a patient’s...
www.fiercebiotech.com
ABBOTT
est cité dans une actualité de FierceBiotech
Le 11/06/2019

ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes

Le 07/06/2019
In its first evaluation of real-world data derived from its FreeStyle Libre continuous glucose monitor in people with Type 2 diabetes, Abbott found that the system was able to significantly reduce...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 22/05/2019

Merck boosts late-phase cancer pipeline with $1.1B Peloton buy

Le 21/05/2019
Merck has struck a deal to buy Peloton Therapeutics for $1.1 billion upfront days before the biotech was due to list on Nasdaq. The deal will give Merck control of an experimental oral HIF-2?...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 17/05/2019

EuroBiotech Report—Bayer's $150M site, Merck, F-star, Philogen round and roxa data

Le 16/05/2019
In this week's EuroBiotech Report, Bayer pumps $150 million into cell therapies, Merck KGaA retools F-star pact and Philogen raises $70 million. ...
www.fiercebiotech.com
Charger plus d'actualités